Monitor for future prospectus supplements that will disclose specific offering terms. The large size relative to market cap suggests this could be a significant dilutive event. Given the company's clinical-stage status and lack of revenue, this capital raise is likely necessary for operations, but represents substantial shareholder dilution risk.
Price Chart
Executive Summary
Oncolytics Biotech filed a shelf registration (S-3) to offer up to $250 million in securities, including common stock, preferred stock, warrants, purchase contracts, and units. This filing replaces a prior registration and carries forward $139 million in unsold securities. The shelf allows the company to raise capital opportunistically over time, signaling potential future dilution.
Key Financial Metrics
Key Facts
- Filed S-3 shelf registration for up to $250 million in securities
- Includes common stock, preferred stock, warrants, purchase contracts, and units
- Carries forward $139 million in unsold securities from a prior registration
- Market cap is $91 million, meaning the offering could result in over 170% dilution if fully utilized
- Recent insider activity shows minimal buying ($15K total)
- Company recently redomesticated to Nevada from Canada
Financial Impact
Up to $250 million in potential dilution, representing 173% of current market cap
Risk Factors
- Significant dilution to existing shareholders if the full $250 million is issued
- Potential for opportunistic timing at low stock prices
- No guaranteed use of proceeds specified, increasing uncertainty
- Clinical-stage biotech with no revenue, increasing investment risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-038078 |
| Document: tm2610569d1_ex3-3.htm | 0001104659-26-038078 |
| Document: tm2610569d1_exfilingfees.htm | 0001104659-26-038078 |
| Document: tm2610569d1_ex5-1.htm | 0001104659-26-038078 |
| Document: tm2610569d1_ex3-2.htm | 0001104659-26-038078 |
| Document: tm2610569d1_ex5-2.htm | 0001104659-26-038078 |
| Document: tm2610569d1_ex23-1.htm | 0001104659-26-038078 |
| Document: 0001104659-26-038078-index-headers.html | 0001104659-26-038078 |
| Document: 0001104659-26-038078-index.html | 0001104659-26-038078 |
| Document: 0001104659-26-038078.txt | 0001104659-26-038078 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access